Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.

Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, Cheung MK, Ni L, Kase S, Rennel ES, Symonds KE, Nowak DG, Royer-Pokora B, Saleem MA, Hagiwara M, Schumacher VA, Harper SJ, Hinton DR, Bates DO, Ladomery MR.

Cancer Cell. 2011 Dec 13;20(6):768-80. doi: 10.1016/j.ccr.2011.10.016.

2.

Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms' Tumor Suppressor Wt1.

Wagner KD, El Maï M, Ladomery M, Belali T, Leccia N, Michiels JF, Wagner N.

Cells. 2019 Jan 11;8(1). pii: E41. doi: 10.3390/cells8010041.

3.

Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.

Mavrou A, Brakspear K, Hamdollah-Zadeh M, Damodaran G, Babaei-Jadidi R, Oxley J, Gillatt DA, Ladomery MR, Harper SJ, Bates DO, Oltean S.

Oncogene. 2015 Aug 13;34(33):4311-9. doi: 10.1038/onc.2014.360. Epub 2014 Nov 10.

4.

Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.

Gammons MV, Lucas R, Dean R, Coupland SE, Oltean S, Bates DO.

Br J Cancer. 2014 Jul 29;111(3):477-85. doi: 10.1038/bjc.2014.342. Epub 2014 Jul 10.

5.

Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis.

Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, Hagiwara M, Harper SJ, Woolard J, Ladomery MR, Bates DO.

J Biol Chem. 2010 Feb 19;285(8):5532-40. doi: 10.1074/jbc.M109.074930. Epub 2009 Nov 11.

6.

Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis.

Manetti M, Guiducci S, Romano E, Ceccarelli C, Bellando-Randone S, Conforti ML, Ibba-Manneschi L, Matucci-Cerinic M.

Circ Res. 2011 Jul 22;109(3):e14-26. doi: 10.1161/CIRCRESAHA.111.242057. Epub 2011 Jun 2.

PMID:
21636803
7.

Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD.

Gammons MV, Fedorov O, Ivison D, Du C, Clark T, Hopkins C, Hagiwara M, Dick AD, Cox R, Harper SJ, Hancox JC, Knapp S, Bates DO.

Invest Ophthalmol Vis Sci. 2013 Sep 5;54(9):6052-62. doi: 10.1167/iovs.13-12422.

8.

VEGF transcription and mRNA stability are altered by WT1 not DDS(R384W) expression in LNCaP cells.

Cash J, Korchnak A, Gorman J, Tandon Y, Fraizer G.

Oncol Rep. 2007 Jun;17(6):1413-9.

PMID:
17487399
9.

Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome.

Schumacher VA, Jeruschke S, Eitner F, Becker JU, Pitschke G, Ince Y, Miner JH, Leuschner I, Engers R, Everding AS, Bulla M, Royer-Pokora B.

J Am Soc Nephrol. 2007 Mar;18(3):719-29. Epub 2007 Jan 31.

10.

A mutant form of the Wilms' tumor suppressor gene WT1 observed in Denys-Drash syndrome interferes with glomerular capillary development.

Natoli TA, Liu J, Eremina V, Hodgens K, Li C, Hamano Y, Mundel P, Kalluri R, Miner JH, Quaggin SE, Kreidberg JA.

J Am Soc Nephrol. 2002 Aug;13(8):2058-67.

11.

Phosphorylation of SRSF1 by SRPK1 regulates alternative splicing of tumor-related Rac1b in colorectal cells.

Gonçalves V, Henriques AF, Pereira JF, Neves Costa A, Moyer MP, Moita LF, Gama-Carvalho M, Matos P, Jordan P.

RNA. 2014 Apr;20(4):474-82. doi: 10.1261/rna.041376.113. Epub 2014 Feb 18. Erratum in: RNA. 2016 Jan;22(1):166. Henriques, Andreia [corrected to Henriques, Andreia F A]; Pereira, Joana [corrected to Pereira, Joana F S].

12.

The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo.

Merdzhanova G, Gout S, Keramidas M, Edmond V, Coll JL, Brambilla C, Brambilla E, Gazzeri S, Eymin B.

Oncogene. 2010 Sep 30;29(39):5392-403. doi: 10.1038/onc.2010.281. Epub 2010 Jul 19.

PMID:
20639906
13.

The role of VEGF 165b in pathophysiology.

Peiris-Pagès M.

Cell Adh Migr. 2012 Nov-Dec;6(6):561-8. doi: 10.4161/cam.22439. Epub 2012 Oct 17. Review.

14.

A murine model of Denys-Drash syndrome reveals novel transcriptional targets of WT1 in podocytes.

Ratelade J, Arrondel C, Hamard G, Garbay S, Harvey S, Biebuyck N, Schulz H, Hastie N, Pontoglio M, Gubler MC, Antignac C, Heidet L.

Hum Mol Genet. 2010 Jan 1;19(1):1-15. doi: 10.1093/hmg/ddp462.

PMID:
19797313
15.

Alternative splicing of SLC39A14 in colorectal cancer is regulated by the Wnt pathway.

Thorsen K, Mansilla F, Schepeler T, Øster B, Rasmussen MH, Dyrskjøt L, Karni R, Akerman M, Krainer AR, Laurberg S, Andersen CL, Ørntoft TF.

Mol Cell Proteomics. 2011 Jan;10(1):M110.002998. doi: 10.1074/mcp.M110.002998. Epub 2010 Oct 11.

16.

Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease.

Batson J, Toop HD, Redondo C, Babaei-Jadidi R, Chaikuad A, Wearmouth SF, Gibbons B, Allen C, Tallant C, Zhang J, Du C, Hancox JC, Hawtrey T, Da Rocha J, Griffith R, Knapp S, Bates DO, Morris JC.

ACS Chem Biol. 2017 Mar 17;12(3):825-832. doi: 10.1021/acschembio.6b01048. Epub 2017 Feb 6.

17.

Transcriptional activity of testis-determining factor SRY is modulated by the Wilms' tumor 1 gene product, WT1.

Matsuzawa-Watanabe Y, Inoue J, Semba K.

Oncogene. 2003 Sep 11;22(39):7900-4.

PMID:
12970737
18.
19.

Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis.

Patek CE, Fleming S, Miles CG, Bellamy CO, Ladomery M, Spraggon L, Mullins J, Hastie ND, Hooper ML.

Hum Mol Genet. 2003 Sep 15;12(18):2379-94. Epub 2003 Jul 22.

PMID:
12915483
20.

Splicing kinase SRPK1 conforms to the landscape of its SR protein substrate.

Aubol BE, Jamros MA, McGlone ML, Adams JA.

Biochemistry. 2013 Oct 29;52(43):7595-605. doi: 10.1021/bi4010864. Epub 2013 Oct 15.

Supplemental Content

Support Center